"The Dialysis Access Institute (DAI) was established at Regional Medical Center in March 2011 to serve patients with end-stage renal disease for whom access to the bloodstream needs to be established or has been compromised. The DAI team performs more than 3,700 procedures/operations each year, and physicians from throughout the world visit RMC to be trained in these procedures. The DAI is accredited by the American Society of Diagnostic & Interventional Nephrology as a hemodialysis vascular access training center. This is the only fulltime, dedicated access center in existence."

During the past decade, Dialysis Access Institute conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 1 clinical trials were completed, i.e. on average, 14.3% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 1 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Dialysis Access Institute" #1 sponsor was "VentureMed Group Inc." with 3 trials, followed by "Artegraft, Inc." with 1 trials sponsored, "Medtronic" with 1 trials sponsored, "Medtronic Endovascular" with 1 trials sponsored and "W.L.Gore & Associates" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

According to Clinical.Site data, the most researched conditions in "Dialysis Access Institute" are "Arteriovenous Fistula Stenosis" (4 trials), "Arteriovenous Fistula" (3 trials), "Arteriovenous Fistula Occlusion" (2 trials), "Fistula" (2 trials) and "Arteriovenous Graft Stenosis" (1 trials). Many other conditions were trialed in "Dialysis Access Institute" in a lesser frequency.

Most popular intervention types in "Dialysis Access Institute" are "Device" (5 trials) and "Combination Product" (2 trials). Other intervention types were less common.

The name of intervention was led by "Angioplasty" (1 trials), "Artegraft® Collagen Vascular Graft™ (Artegraft)" (1 trials), "FLEX Scoring Catheter with Lutonix DCB" (1 trials), "FLEX Vessel Prep System" (1 trials) and "FLEX Vessel Prep System followed by angioplasty" (1 trials). Other intervention names were less common.

The vast majority of trials in "Dialysis Access Institute" are 7 trials for "All" genders.

Currently, there are NaN active trials in "Dialysis Access Institute". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Dialysis Access Institute, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Dialysis Access Institute, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".